Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].

Core Viewpoint - A class action lawsuit has been filed against Civitas Resources, Inc. for allegedly misleading investors about its production capabilities and financial condition during the specified class period [1][2]. Allegations - Civitas is accused of failing to disclose significant reductions in oil production expected in 2025 due to declines after a production peak in Q4 2024 and a low TIL count at the end of 2024 [2]. - The company would need to acquire additional acreage and development locations to increase oil production, which would incur significant debt and potentially require selling corporate assets [2]. - Financial conditions would necessitate disruptive cost-reduction measures, including a significant workforce reduction [2]. - The company's business and financial prospects, as well as operational capabilities, were allegedly overstated [2]. Stock Price Impact - Following the revelation of these issues on February 24, 2025, Civitas's stock price dropped by $8.95 per share, representing a decline of over 18%, closing at $40.35 per share on February 25, 2025 [2]. Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by July 1, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Company Background - Civitas Resources, Inc. is an independent exploration and production company focused on crude oil and liquids-rich natural gas in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [1].

Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]

Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly misleading investors about customer growth and strategic initiatives [1][2]. Allegations - The complaint claims that Vestis Corporation did not disclose its inability to execute planned strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and retention [2]. - It is alleged that these misleading statements led to investors purchasing Vestis securities at artificially inflated prices [2]. Financial Results and Market Reaction - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue guidance for the full year, and provided third-quarter guidance that was significantly below market expectations [3]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Company Background - Robbins LLP, the firm leading the class action, specializes in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [5].

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Red Cat Holdings, Inc. (NASDAQ: RCAT) and Fortrea Holdings Inc. (NASDAQ:FTRE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Red Cat Holdings, Inc. (NASDAQ: RCAT) Class Period: M ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence in failing to warn about the risks associated with cow's milk-based formula, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC-related damages, Reckitt's ADS price also experienced a notable decline [4]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file a motion by August 4, 2025, but participation is not required to be eligible for recovery [5].

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025. Red Cat, together with its subsidiaries, provides various products, services, and solutions to the U.S. drone industry. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased NET Power Inc. securities between June 9, 2023, and March 7, 2025, alleging that the company misled investors regarding the timeline and costs associated with Project Permian [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that NET Power failed to disclose that Project Permian was unlikely to be completed on schedule and would incur significantly higher costs due to supply chain issues and site-specific challenges [2]. - Following the announcement of third quarter 2023 results, NET Power's stock fell over 18% after revealing a 12-month delay in the project timeline, now expecting initial power generation between the second half of 2027 and first half of 2028 [3]. - On March 10, 2025, NET Power disclosed that the total installed cost for Project Permian is now estimated to be between $1.7 billion and $2.0 billion, a significant increase from the previous estimate of $1.1 billion, and announced a further delay to no earlier than 2029, causing the stock price to drop over 31% [4]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 17, 2025, although participation is not required to be eligible for recovery [5].